(Q38180027)

30 August 2017

title

Sofosbuvir: first global approval (English)

1 reference

30 August 2017

0 references

1

Gillian M Keating

1 reference

30 August 2017

Asha Vaidya

2

1 reference

30 August 2017

publication date

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

273-282

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Current prospects for interferon-free treatment of hepatitis C in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Interferon-free hepatitis C therapy: how close are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir-based interferon-free therapy for patients with HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0179-7

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24442794

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-014-0179-7

1 reference

Dimensions Publication ID

30 August 2017

1022521839

0 references

1 reference